Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Locoregional delivery of IL-13Rα2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial

Nature Medicine(2024)10.1038/s41591-024-02875-1Source: DataRank Database

Locoregional delivery of IL-13Rα2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial is a research paper published in Nature Medicine (2024). On theSindex it has a DataRank of 3.8. It has been cited 308 times, with 100 citing works in its 1-hop citation network.

N/A

3.8DataRank · unranked

Scored on demand from live citation data

Deposits data Open Access308 citations · 100 citing works in its network

Download PDF

Cite:

Linked data & code

nct

Data availability

Repositories this paper deposited data in (declared in PubMed).

ClinicalTrials.govNCT02208362
GEOGSE255850

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (17 grants)OA: hybridTopics (78)IDs (PubMed, PMC)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 22%Citation Network 78%

Base Score Contribution

0.860

From this paper's citation signal

Citation Network Contribution

3.0

From 100 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 100 citers.

Next-generation CAR T cell therapies for glioblastoma
Science Translational Medicine202411 citations10 referencesContributes 0.248
Intracranial CAR-T cell delivery in glioblastoma patients
Trends in cancer20245 citations11 referencesContributes 0.163
CAR T cell therapy for glioblastoma: A review of the first decade of clinical trials
Molecular Therapy202536 citations28 referencesContributes 0.129
Intravenous and intracranial GD2-CAR T cells for H3K27M+ diffuse midline gliomas
Nature2024185 citations45 referencesContributes 0.116
Locoregional delivery of chimeric antigen receptor-T cells: Breaking the spell in glioblastoma?
Neuro-Oncology20245 citations17 referencesContributes 0.105

Authors (30)

Jonathan Hibbard,Darya Alizadeh ORCID,M. Suzette Blanchard,Heini M. Natri ORCID,Dongrui Wang ORCID

Live enrichment

PubMed:38454126 PMC:PMC11031404

California Institute for Regenerative Medicine

Grant: CLIN2-12153

Gateway for Cancer Research

Grant: G-14-600

U.S. Department of Health & Human Services | U.S. Food and Drug Administration

Grant: R01FD005129

U.S. Department of Health & Human Services | NIH | National Cancer Institute

Grant: K12CA001727

U.S. Department of Health & Human Services | NIH | National Cancer Institute

Grant: R01CA155769

NHLBI NIH HHS

Grant: 75N92019D00018

NINDS NIH HHS

Grant: R21 NS081594

NCI NIH HHS

Grant: R21 CA189223

NCI NIH HHS

Grant: P30 CA033572

NCI NIH HHS

Grant: R01 CA236500

National Institutes of Health

Grant: 1R21CA189223-01A1

Novel Cell Delivery Method for Brain Tumor Therapy

National Institutes of Health

Grant: 5R21NS081594-02

Dynamic Magnetic Targeting of Activated Brain Macrophages for Glioma Therapy

National Institutes of Health

Grant: 5R01CA236500-06

Clinical evaluation of IL13Ra2-targeted CAR T cell therapy in combination with nivolumab in patients with recurrent malignant glioma

National Institutes of Health

Grant: 5R01CA155769-09

Role of Receptor for Advanced Glycation End Product (RAGE) Pathway in Brain Tumors

National Institutes of Health

Grant: 2K12CA001727-16A1

City of Hope Clinical Oncology Career Research Development Program

National Institutes of Health

Grant: 5P30CA033572-27

Developmental Funds

National Institutes of Health

Grant: 5R01FD005129-03

Phase 1 Study of Cellular Immunotherapy Using Optimized IL13Ra2 Specific CAR T cells for the Treatment of Malignant Glioma

hybridLicense: cc-by

publisherhttps://www.nature.com/articles/s41591-024-02875-1.pdf

publisherhttps://www.nature.com/articles/s41591-024-02875-1

repositoryhttps://escholarship.org/content/qt9r58c262/qt9r58c262.pdf

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC11031404/pdf/41591_2024_Article_2875.pdf

Europe_PMChttps://europepmc.org/articles/PMC11031404

Fields of Study

0301 basic medicine0303 health sciences03 medical and health sciences

MeSH Terms

T-LymphocytesHumansGliomaGlioblastomaNeoplasm Recurrence, LocalImmunotherapy, AdoptiveReceptors, Chimeric Antigen

Keywords

T-LymphocytesAdoptiveHealth Disparities (rcdc)11 Medical and Health Sciences (for)Medical and Health SciencesImmunotherapy, AdoptiveAdoptive (mesh)Clinical Research (rcdc)Brain Disorders (rcdc)ReceptorsGlioma (mesh)Minority HealthT-Lymphocytes (mesh)32 Biomedical and Clinical Sciences (for-2020)6.2 Cellular and gene therapiesNeurosciences (rcdc)CancerCancer (rcdc)Brain Cancer (rcdc)Humans (mesh)Receptors, Chimeric AntigenGene TherapyGliomaHealth DisparitiesLocalGlioblastoma (mesh)6.1 PharmaceuticalsChimeric Antigen (mesh)Minority Health (rcdc)ImmunotherapyBiotechnologyImmunology (science-metrix)Clinical SciencesOncology and CarcinogenesisImmunologyClinical Trials and Supportive ActivitiesClinical Trials and Supportive Activities (rcdc)610Biotechnology (rcdc)ArticleRare Diseases (rcdc)6.2 Cellular and gene therapies (hrcs-rac)Rare DiseasesClinical Research42 Health sciences (for-2020)616GeneticsHumans3204 Immunology (for-2020)3202 Clinical Sciences (for-2020)6.1 Pharmaceuticals (hrcs-rac)Biomedical and Clinical SciencesGenetics (rcdc)NeurosciencesChimeric AntigenHealth sciencesImmunotherapy (rcdc)Cancer (hrcs-hc)Brain DisordersGene Therapy (rcdc)Brain CancerOrphan Drug3211 Oncology and Carcinogenesis (for-2020)Neoplasm RecurrenceOrphan Drug (rcdc)Local (mesh)Neoplasm Recurrence, LocalGlioblastoma

Sustainable Development Goals

SDG 3: 3. Good health